Biotechs climb after two-day drop

Traders gather at the post where Alibaba Group Holding Ltd is traded on the floor of the New York Stock ExchangeBy Chuck Mikolajczak NEW YORK (Reuters) – Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment. Gilead said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies, sending shares up 2.5 percent to $ 108.06. Of the 119 stocks that comprise the Nasdaq biotech index, only 10 were in negative territory. The gains helped lift the biotech index 2.4 percent, putting it on track for its best day in two months. …



Sexual Health News Headlines – Yahoo! News